What is HC Wainwright’s Forecast for CHRN Q2 Earnings?

ChronoScale Corporation Common Stock (NASDAQ:CHRN) – Equities researchers at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of ChronoScale Corporation Common Stock in a report released on Monday, June 15th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright also issued estimates for ChronoScale Corporation Common Stock’s Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.10) EPS, FY2027 earnings at ($0.06) EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.14 EPS.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its quarterly earnings data on Tuesday, April 28th. The company reported ($2.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($2.01). The business had revenue of $2.14 million for the quarter, compared to analysts’ expectations of $4.29 million. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ChronoScale Corporation Common Stock in a research note on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ChronoScale Corporation Common Stock currently has an average rating of “Reduce” and a consensus price target of $6.00.

ChronoScale Corporation Common Stock Price Performance

CHRN opened at $25.75 on Wednesday. The company has a market capitalization of $91.67 million, a price-to-earnings ratio of -4.79 and a beta of 1.02. The company has a quick ratio of 1.03, a current ratio of 1.55 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average price of $15.87 and a 200-day moving average price of $11.31. ChronoScale Corporation Common Stock has a twelve month low of $2.73 and a twelve month high of $28.20.

Institutional Investors Weigh In On ChronoScale Corporation Common Stock

Institutional investors and hedge funds have recently made changes to their positions in the business. Roble Belko & Company Inc boosted its stake in ChronoScale Corporation Common Stock by 104.5% during the first quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock valued at $25,000 after buying an additional 1,195 shares during the period. Virtu Financial LLC bought a new position in ChronoScale Corporation Common Stock in the 3rd quarter worth about $57,000. Shay Capital LLC bought a new position in ChronoScale Corporation Common Stock in the 3rd quarter worth about $67,000. Citadel Advisors LLC purchased a new stake in shares of ChronoScale Corporation Common Stock in the 3rd quarter valued at about $198,000. Finally, Geode Capital Management LLC raised its holdings in shares of ChronoScale Corporation Common Stock by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after acquiring an additional 10,281 shares in the last quarter. Hedge funds and other institutional investors own 6.42% of the company’s stock.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.